The Experts below are selected from a list of 27546 Experts worldwide ranked by ideXlab platform
Sigrid Karrer - One of the best experts on this subject based on the ideXlab platform.
-
investigation of toxicity and mutagenicity of cold atmospheric Argon Plasma
Environmental and Molecular Mutagenesis, 2017Co-Authors: Tim Maisch, G E Morfill, Michael Landthaler, Tetsuji Shimizu, Anjakatrin Bosserhoff, Petra Unger, J Heider, Julia L Zimmermann, Sigrid KarrerAbstract:Cold atmospheric Argon Plasma is recognized as a new contact free approach for the decrease of bacterial load on chronic wounds in patients. So far very limited data are available on its toxicity and mutagenicity on eukaryotic cells. Thus, the toxic/mutagenic potential of cold atmospheric Argon Plasma using the MicroPlaSter β® , which has been used efficiently in humans treating chronic and acute wounds, was investigated using the XTT assay in keratinocytes and fibroblasts and the HGPRT (hypoxanthine guanine phosphoribosyl transferase) assay with V79 Chinese hamster cells. The tested clinical parameter of a 2 min cold atmospheric Argon Plasma treatment revealed no relevant toxicity on keratinocytes (viability: 76% ± 0.17%) and on fibroblasts (viability: 81.8 ± 0.10) after 72 hr as compared to the untreated controls. No mutagenicity was detected in the HGPRT assay with V79 cells even after repetitive CAP treatments of 2-10 min every 24 hr for up to 5 days. In contrast, UV-C irradiation of V79 cells, used as a positive control in the HGPRT test, led to DNA damage and mutagenic effects. Our findings indicate that cold atmospheric Plasma using the MicroPlaSter β® shows negligible effects on keratinocytes and fibroblasts but no mutagenic potential in the HGPRT assay, indicating a new contact free safe technology. Environ. Mol. Mutagen. 58:172-177, 2017. © 2017 Wiley Periodicals, Inc.
-
randomized placebo controlled clinical trial showed cold atmospheric Argon Plasma relieved acute pain and accelerated healing in herpes zoster
Clinical Plasma Medicine, 2014Co-Authors: Georg Isbary, G E Morfill, J Heinlin, Sigrid Karrer, Tetsuji Shimizu, Julia L Zimmermann, S Alzaabi, M Rechfeld, Wilhelm StolzAbstract:Herpes zoster is an acute painful infectious skin condition due to the reactivation of the varicella zoster virus, with increasing incidence in the aging population. Acute pain relief is usually required and post-herpetic neuralgia requiring ongoing analgesia is a well recognised complication. Argon Plasma treatment has demonstrated efficacy in reducing bacterial load in chronic wounds, and possibly stimulating wound healing. In this study, weekday 5 min Plasma treatments with the MicroPlaSter s device was assessed for safety, pain reduction and healing rates of herpes zoster. 37 inpatients with herpes zoster were treated in a prospective randomized placebo-controlled phase II study with either weekday 5 min of cold atmospheric Argon Plasma (19, active) or with 5 min of Argon gas (18, placebo), in addition to a standard treatment regime. Pain was assessed by visual analogue scale before and after active or placebo application. Digital images of lesions were evaluated independently by three blinded clinicians, with regard to vesicles, erythema and general impression. Analysis revealed a significantly greater (p<0.01) reduction in pain in Plasma-treated patients compared to controls over the course of treatment, and a significantly better median reduction immediately after each treatment (p<0.05). Plasma treatment led to more rapid clinical improvement in the first 1–2 days. Weekday 5 min treatments with cold atmospheric Argon Plasma was safe, painless and effective, improving initial healing and acute pain in herpes zoster lesions.
-
a first prospective randomized controlled trial to decrease bacterial load using cold atmospheric Argon Plasma on chronic wounds in patients
British Journal of Dermatology, 2010Co-Authors: Georg Isbary, G E Morfill, Hansulrich Schmidt, Matthias Georgi, Katrin Ramrath, J Heinlin, Sigrid Karrer, Michael Landthaler, Tetsuji Shimizu, Bernd SteffesAbstract:Summary Background Bacterial colonization of chronic wounds slows healing. Cold atmospheric Plasma has been shown in vitro to kill a wide range of pathogenic bacteria. Objectives To examine the safety and efficiency of cold atmospheric Argon Plasma to decrease bacterial load as a new medical treatment for chronic wounds. Patients and methods Thirty-eight chronic infected wounds in 36 patients were treated in a prospective randomized controlled phase II study with 5 min daily cold atmospheric Argon Plasma in addition to standard wound care. The patient acted as his or her own control. Bacterial species were detected by standard bacterial swabs and semiquantitative changes by nitrocellulose filters. Plasma setting and safety had been determined in a preceding phase I study. Results Analysis of 291 treatments in 38 wounds found a highly significant (34%, P < 10−6) reduction of bacterial load in treated wounds, regardless of the type of bacteria. No side-effects occurred and the treatment was well tolerated. Conclusions Cold atmospheric Argon Plasma treatment is potentially a safe and painless new technique to decrease bacterial load of chronic wounds and promote healing.
Tetsuji Shimizu - One of the best experts on this subject based on the ideXlab platform.
-
investigation of toxicity and mutagenicity of cold atmospheric Argon Plasma
Environmental and Molecular Mutagenesis, 2017Co-Authors: Tim Maisch, G E Morfill, Michael Landthaler, Tetsuji Shimizu, Anjakatrin Bosserhoff, Petra Unger, J Heider, Julia L Zimmermann, Sigrid KarrerAbstract:Cold atmospheric Argon Plasma is recognized as a new contact free approach for the decrease of bacterial load on chronic wounds in patients. So far very limited data are available on its toxicity and mutagenicity on eukaryotic cells. Thus, the toxic/mutagenic potential of cold atmospheric Argon Plasma using the MicroPlaSter β® , which has been used efficiently in humans treating chronic and acute wounds, was investigated using the XTT assay in keratinocytes and fibroblasts and the HGPRT (hypoxanthine guanine phosphoribosyl transferase) assay with V79 Chinese hamster cells. The tested clinical parameter of a 2 min cold atmospheric Argon Plasma treatment revealed no relevant toxicity on keratinocytes (viability: 76% ± 0.17%) and on fibroblasts (viability: 81.8 ± 0.10) after 72 hr as compared to the untreated controls. No mutagenicity was detected in the HGPRT assay with V79 cells even after repetitive CAP treatments of 2-10 min every 24 hr for up to 5 days. In contrast, UV-C irradiation of V79 cells, used as a positive control in the HGPRT test, led to DNA damage and mutagenic effects. Our findings indicate that cold atmospheric Plasma using the MicroPlaSter β® shows negligible effects on keratinocytes and fibroblasts but no mutagenic potential in the HGPRT assay, indicating a new contact free safe technology. Environ. Mol. Mutagen. 58:172-177, 2017. © 2017 Wiley Periodicals, Inc.
-
randomized placebo controlled clinical trial showed cold atmospheric Argon Plasma relieved acute pain and accelerated healing in herpes zoster
Clinical Plasma Medicine, 2014Co-Authors: Georg Isbary, G E Morfill, J Heinlin, Sigrid Karrer, Tetsuji Shimizu, Julia L Zimmermann, S Alzaabi, M Rechfeld, Wilhelm StolzAbstract:Herpes zoster is an acute painful infectious skin condition due to the reactivation of the varicella zoster virus, with increasing incidence in the aging population. Acute pain relief is usually required and post-herpetic neuralgia requiring ongoing analgesia is a well recognised complication. Argon Plasma treatment has demonstrated efficacy in reducing bacterial load in chronic wounds, and possibly stimulating wound healing. In this study, weekday 5 min Plasma treatments with the MicroPlaSter s device was assessed for safety, pain reduction and healing rates of herpes zoster. 37 inpatients with herpes zoster were treated in a prospective randomized placebo-controlled phase II study with either weekday 5 min of cold atmospheric Argon Plasma (19, active) or with 5 min of Argon gas (18, placebo), in addition to a standard treatment regime. Pain was assessed by visual analogue scale before and after active or placebo application. Digital images of lesions were evaluated independently by three blinded clinicians, with regard to vesicles, erythema and general impression. Analysis revealed a significantly greater (p<0.01) reduction in pain in Plasma-treated patients compared to controls over the course of treatment, and a significantly better median reduction immediately after each treatment (p<0.05). Plasma treatment led to more rapid clinical improvement in the first 1–2 days. Weekday 5 min treatments with cold atmospheric Argon Plasma was safe, painless and effective, improving initial healing and acute pain in herpes zoster lesions.
-
successful and safe use of 2 min cold atmospheric Argon Plasma in chronic wounds results of a randomized controlled trial
British Journal of Dermatology, 2012Co-Authors: Georg Isbary, G E Morfill, Hansulrich Schmidt, J Heinlin, Tetsuji Shimizu, Bernd Steffes, Julia L Zimmermann, Roberto Monetti, W Bunk, Yuchuan LiAbstract:Background The development of antibiotic resistance by microorganisms is an increasing problem in medicine. In chronic wounds, bacterial colonization is associated with impaired healing. Cold atmospheric Plasma is an innovative promising tool to deal with these problems. Objectives The 5-min Argon Plasma treatment has already demonstrated efficacy in reducing bacterial numbers in chronic infected wounds in vivo. In this study we investigated a 2-min Plasma treatment with the same device and the next-generation device, to assess safety and reduction in bacterial load, regardless of the kind of bacteria and their resistance level in chronic wounds. Methods Twenty-four patients with chronic infected wounds were treated in a prospective randomized controlled phase II study with 2 min of cold atmospheric Argon Plasma every day: 14 with MicroPlaSter alpha device, 10 with MicroPlaSter beta device (next-generation device) in addition to standard wound care. The patient acted as his ⁄her own control. Bacterial species were detected by standard bacterial swabs and bacterial load by semiquantitative count on nitrocellulose filters. The Plasma settings were the same as in the previous phase II study in which wounds were exposed for 5 min to Argon Plasma. Results Analysis of 70 treatments in 14 patients with the MicroPlaSter alpha device revealed a significant (40%, P <0 AE016) reduction in bacterial load in Plasmatreated wounds, regardless of the species of bacteria. Analysis of 137 treatments in 10 patients with the MicroPlaSter beta device showed a highly significant reduction (23AE5%, P <0 AE008) in bacterial load. No side-effects occurred and the treatment was well tolerated. Conclusions A 2-min treatment with either of two cold atmospheric Argon Plasma devices is a safe, painless and effective technique to decrease the bacterial load in chronic wounds.
-
a first prospective randomized controlled trial to decrease bacterial load using cold atmospheric Argon Plasma on chronic wounds in patients
British Journal of Dermatology, 2010Co-Authors: Georg Isbary, G E Morfill, Hansulrich Schmidt, Matthias Georgi, Katrin Ramrath, J Heinlin, Sigrid Karrer, Michael Landthaler, Tetsuji Shimizu, Bernd SteffesAbstract:Summary Background Bacterial colonization of chronic wounds slows healing. Cold atmospheric Plasma has been shown in vitro to kill a wide range of pathogenic bacteria. Objectives To examine the safety and efficiency of cold atmospheric Argon Plasma to decrease bacterial load as a new medical treatment for chronic wounds. Patients and methods Thirty-eight chronic infected wounds in 36 patients were treated in a prospective randomized controlled phase II study with 5 min daily cold atmospheric Argon Plasma in addition to standard wound care. The patient acted as his or her own control. Bacterial species were detected by standard bacterial swabs and semiquantitative changes by nitrocellulose filters. Plasma setting and safety had been determined in a preceding phase I study. Results Analysis of 291 treatments in 38 wounds found a highly significant (34%, P < 10−6) reduction of bacterial load in treated wounds, regardless of the type of bacteria. No side-effects occurred and the treatment was well tolerated. Conclusions Cold atmospheric Argon Plasma treatment is potentially a safe and painless new technique to decrease bacterial load of chronic wounds and promote healing.
G E Morfill - One of the best experts on this subject based on the ideXlab platform.
-
investigation of toxicity and mutagenicity of cold atmospheric Argon Plasma
Environmental and Molecular Mutagenesis, 2017Co-Authors: Tim Maisch, G E Morfill, Michael Landthaler, Tetsuji Shimizu, Anjakatrin Bosserhoff, Petra Unger, J Heider, Julia L Zimmermann, Sigrid KarrerAbstract:Cold atmospheric Argon Plasma is recognized as a new contact free approach for the decrease of bacterial load on chronic wounds in patients. So far very limited data are available on its toxicity and mutagenicity on eukaryotic cells. Thus, the toxic/mutagenic potential of cold atmospheric Argon Plasma using the MicroPlaSter β® , which has been used efficiently in humans treating chronic and acute wounds, was investigated using the XTT assay in keratinocytes and fibroblasts and the HGPRT (hypoxanthine guanine phosphoribosyl transferase) assay with V79 Chinese hamster cells. The tested clinical parameter of a 2 min cold atmospheric Argon Plasma treatment revealed no relevant toxicity on keratinocytes (viability: 76% ± 0.17%) and on fibroblasts (viability: 81.8 ± 0.10) after 72 hr as compared to the untreated controls. No mutagenicity was detected in the HGPRT assay with V79 cells even after repetitive CAP treatments of 2-10 min every 24 hr for up to 5 days. In contrast, UV-C irradiation of V79 cells, used as a positive control in the HGPRT test, led to DNA damage and mutagenic effects. Our findings indicate that cold atmospheric Plasma using the MicroPlaSter β® shows negligible effects on keratinocytes and fibroblasts but no mutagenic potential in the HGPRT assay, indicating a new contact free safe technology. Environ. Mol. Mutagen. 58:172-177, 2017. © 2017 Wiley Periodicals, Inc.
-
randomized placebo controlled clinical trial showed cold atmospheric Argon Plasma relieved acute pain and accelerated healing in herpes zoster
Clinical Plasma Medicine, 2014Co-Authors: Georg Isbary, G E Morfill, J Heinlin, Sigrid Karrer, Tetsuji Shimizu, Julia L Zimmermann, S Alzaabi, M Rechfeld, Wilhelm StolzAbstract:Herpes zoster is an acute painful infectious skin condition due to the reactivation of the varicella zoster virus, with increasing incidence in the aging population. Acute pain relief is usually required and post-herpetic neuralgia requiring ongoing analgesia is a well recognised complication. Argon Plasma treatment has demonstrated efficacy in reducing bacterial load in chronic wounds, and possibly stimulating wound healing. In this study, weekday 5 min Plasma treatments with the MicroPlaSter s device was assessed for safety, pain reduction and healing rates of herpes zoster. 37 inpatients with herpes zoster were treated in a prospective randomized placebo-controlled phase II study with either weekday 5 min of cold atmospheric Argon Plasma (19, active) or with 5 min of Argon gas (18, placebo), in addition to a standard treatment regime. Pain was assessed by visual analogue scale before and after active or placebo application. Digital images of lesions were evaluated independently by three blinded clinicians, with regard to vesicles, erythema and general impression. Analysis revealed a significantly greater (p<0.01) reduction in pain in Plasma-treated patients compared to controls over the course of treatment, and a significantly better median reduction immediately after each treatment (p<0.05). Plasma treatment led to more rapid clinical improvement in the first 1–2 days. Weekday 5 min treatments with cold atmospheric Argon Plasma was safe, painless and effective, improving initial healing and acute pain in herpes zoster lesions.
-
successful and safe use of 2 min cold atmospheric Argon Plasma in chronic wounds results of a randomized controlled trial
British Journal of Dermatology, 2012Co-Authors: Georg Isbary, G E Morfill, Hansulrich Schmidt, J Heinlin, Tetsuji Shimizu, Bernd Steffes, Julia L Zimmermann, Roberto Monetti, W Bunk, Yuchuan LiAbstract:Background The development of antibiotic resistance by microorganisms is an increasing problem in medicine. In chronic wounds, bacterial colonization is associated with impaired healing. Cold atmospheric Plasma is an innovative promising tool to deal with these problems. Objectives The 5-min Argon Plasma treatment has already demonstrated efficacy in reducing bacterial numbers in chronic infected wounds in vivo. In this study we investigated a 2-min Plasma treatment with the same device and the next-generation device, to assess safety and reduction in bacterial load, regardless of the kind of bacteria and their resistance level in chronic wounds. Methods Twenty-four patients with chronic infected wounds were treated in a prospective randomized controlled phase II study with 2 min of cold atmospheric Argon Plasma every day: 14 with MicroPlaSter alpha device, 10 with MicroPlaSter beta device (next-generation device) in addition to standard wound care. The patient acted as his ⁄her own control. Bacterial species were detected by standard bacterial swabs and bacterial load by semiquantitative count on nitrocellulose filters. The Plasma settings were the same as in the previous phase II study in which wounds were exposed for 5 min to Argon Plasma. Results Analysis of 70 treatments in 14 patients with the MicroPlaSter alpha device revealed a significant (40%, P <0 AE016) reduction in bacterial load in Plasmatreated wounds, regardless of the species of bacteria. Analysis of 137 treatments in 10 patients with the MicroPlaSter beta device showed a highly significant reduction (23AE5%, P <0 AE008) in bacterial load. No side-effects occurred and the treatment was well tolerated. Conclusions A 2-min treatment with either of two cold atmospheric Argon Plasma devices is a safe, painless and effective technique to decrease the bacterial load in chronic wounds.
-
a first prospective randomized controlled trial to decrease bacterial load using cold atmospheric Argon Plasma on chronic wounds in patients
British Journal of Dermatology, 2010Co-Authors: Georg Isbary, G E Morfill, Hansulrich Schmidt, Matthias Georgi, Katrin Ramrath, J Heinlin, Sigrid Karrer, Michael Landthaler, Tetsuji Shimizu, Bernd SteffesAbstract:Summary Background Bacterial colonization of chronic wounds slows healing. Cold atmospheric Plasma has been shown in vitro to kill a wide range of pathogenic bacteria. Objectives To examine the safety and efficiency of cold atmospheric Argon Plasma to decrease bacterial load as a new medical treatment for chronic wounds. Patients and methods Thirty-eight chronic infected wounds in 36 patients were treated in a prospective randomized controlled phase II study with 5 min daily cold atmospheric Argon Plasma in addition to standard wound care. The patient acted as his or her own control. Bacterial species were detected by standard bacterial swabs and semiquantitative changes by nitrocellulose filters. Plasma setting and safety had been determined in a preceding phase I study. Results Analysis of 291 treatments in 38 wounds found a highly significant (34%, P < 10−6) reduction of bacterial load in treated wounds, regardless of the type of bacteria. No side-effects occurred and the treatment was well tolerated. Conclusions Cold atmospheric Argon Plasma treatment is potentially a safe and painless new technique to decrease bacterial load of chronic wounds and promote healing.
Georg Isbary - One of the best experts on this subject based on the ideXlab platform.
-
randomized placebo controlled clinical trial showed cold atmospheric Argon Plasma relieved acute pain and accelerated healing in herpes zoster
Clinical Plasma Medicine, 2014Co-Authors: Georg Isbary, G E Morfill, J Heinlin, Sigrid Karrer, Tetsuji Shimizu, Julia L Zimmermann, S Alzaabi, M Rechfeld, Wilhelm StolzAbstract:Herpes zoster is an acute painful infectious skin condition due to the reactivation of the varicella zoster virus, with increasing incidence in the aging population. Acute pain relief is usually required and post-herpetic neuralgia requiring ongoing analgesia is a well recognised complication. Argon Plasma treatment has demonstrated efficacy in reducing bacterial load in chronic wounds, and possibly stimulating wound healing. In this study, weekday 5 min Plasma treatments with the MicroPlaSter s device was assessed for safety, pain reduction and healing rates of herpes zoster. 37 inpatients with herpes zoster were treated in a prospective randomized placebo-controlled phase II study with either weekday 5 min of cold atmospheric Argon Plasma (19, active) or with 5 min of Argon gas (18, placebo), in addition to a standard treatment regime. Pain was assessed by visual analogue scale before and after active or placebo application. Digital images of lesions were evaluated independently by three blinded clinicians, with regard to vesicles, erythema and general impression. Analysis revealed a significantly greater (p<0.01) reduction in pain in Plasma-treated patients compared to controls over the course of treatment, and a significantly better median reduction immediately after each treatment (p<0.05). Plasma treatment led to more rapid clinical improvement in the first 1–2 days. Weekday 5 min treatments with cold atmospheric Argon Plasma was safe, painless and effective, improving initial healing and acute pain in herpes zoster lesions.
-
successful and safe use of 2 min cold atmospheric Argon Plasma in chronic wounds results of a randomized controlled trial
British Journal of Dermatology, 2012Co-Authors: Georg Isbary, G E Morfill, Hansulrich Schmidt, J Heinlin, Tetsuji Shimizu, Bernd Steffes, Julia L Zimmermann, Roberto Monetti, W Bunk, Yuchuan LiAbstract:Background The development of antibiotic resistance by microorganisms is an increasing problem in medicine. In chronic wounds, bacterial colonization is associated with impaired healing. Cold atmospheric Plasma is an innovative promising tool to deal with these problems. Objectives The 5-min Argon Plasma treatment has already demonstrated efficacy in reducing bacterial numbers in chronic infected wounds in vivo. In this study we investigated a 2-min Plasma treatment with the same device and the next-generation device, to assess safety and reduction in bacterial load, regardless of the kind of bacteria and their resistance level in chronic wounds. Methods Twenty-four patients with chronic infected wounds were treated in a prospective randomized controlled phase II study with 2 min of cold atmospheric Argon Plasma every day: 14 with MicroPlaSter alpha device, 10 with MicroPlaSter beta device (next-generation device) in addition to standard wound care. The patient acted as his ⁄her own control. Bacterial species were detected by standard bacterial swabs and bacterial load by semiquantitative count on nitrocellulose filters. The Plasma settings were the same as in the previous phase II study in which wounds were exposed for 5 min to Argon Plasma. Results Analysis of 70 treatments in 14 patients with the MicroPlaSter alpha device revealed a significant (40%, P <0 AE016) reduction in bacterial load in Plasmatreated wounds, regardless of the species of bacteria. Analysis of 137 treatments in 10 patients with the MicroPlaSter beta device showed a highly significant reduction (23AE5%, P <0 AE008) in bacterial load. No side-effects occurred and the treatment was well tolerated. Conclusions A 2-min treatment with either of two cold atmospheric Argon Plasma devices is a safe, painless and effective technique to decrease the bacterial load in chronic wounds.
-
a first prospective randomized controlled trial to decrease bacterial load using cold atmospheric Argon Plasma on chronic wounds in patients
British Journal of Dermatology, 2010Co-Authors: Georg Isbary, G E Morfill, Hansulrich Schmidt, Matthias Georgi, Katrin Ramrath, J Heinlin, Sigrid Karrer, Michael Landthaler, Tetsuji Shimizu, Bernd SteffesAbstract:Summary Background Bacterial colonization of chronic wounds slows healing. Cold atmospheric Plasma has been shown in vitro to kill a wide range of pathogenic bacteria. Objectives To examine the safety and efficiency of cold atmospheric Argon Plasma to decrease bacterial load as a new medical treatment for chronic wounds. Patients and methods Thirty-eight chronic infected wounds in 36 patients were treated in a prospective randomized controlled phase II study with 5 min daily cold atmospheric Argon Plasma in addition to standard wound care. The patient acted as his or her own control. Bacterial species were detected by standard bacterial swabs and semiquantitative changes by nitrocellulose filters. Plasma setting and safety had been determined in a preceding phase I study. Results Analysis of 291 treatments in 38 wounds found a highly significant (34%, P < 10−6) reduction of bacterial load in treated wounds, regardless of the type of bacteria. No side-effects occurred and the treatment was well tolerated. Conclusions Cold atmospheric Argon Plasma treatment is potentially a safe and painless new technique to decrease bacterial load of chronic wounds and promote healing.
Shou Z Li - One of the best experts on this subject based on the ideXlab platform.
-
sterilization of bacterial endospores by an atmospheric pressure Argon Plasma jet
Applied Physics Letters, 2007Co-Authors: Shou Z LiAbstract:Argon Plasma jets penetrate deep into ambient air and create a path for oxygen radicals to sterilize microbes. A sterilization experiment with bacterial endospores indicates that an Argon-oxygen Plasma jet very effectively kills endospores of Bacillus atrophaeus (ATCC 9372), thereby demonstrating its capability to clean surfaces and its usefulness for reinstating contaminated equipment as free from toxic biological warfare agents. However, the spore-killing efficiency of the atmospheric-pressure Argon-oxygen jet depends very sensitively on the oxygen concentration in the Argon gas.